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A Surprising Twist on Bacteriophage Therapy
Bacterial infections have always been a threat to human health. The first available systemic
antibiotics, in early twentieth century, were initially seen as truly miraculous drugs, providing a
powerful tool to combat bacterial infections and increasing human life span. Deluded by their
exceptional antimicrobial properties, they quickly fell in trivial use to fight even the most common
types of infections, many of non-bacterial nature. This indiscriminate use of antibiotics allowed
bacteria to develop defense systems to become less prone to antibiotics - multiresistant-superbugs,
a development that Sir Alexander Fleming already anticipated when he gave his Nobel lecture in
1945.
Bacteriophages (phages) are natural predators of bacteria that specifically parasite bacteria
to replicate, and were discovered in the early part of the twentieth century, independently
by Twort (1915) and d’Herelle (1917) (Summers, 2005). The ability to kill bacteria was soon
therapeutically explored by d’Hérelle and his followers while fighting various bacterial infections
around the world, such as the bubonic plague in Southeast Asia, dysentery in France, and
cholera in India. Phage therapy was extensively used to treat infectious diseases during World
War II too (Summers, 2001). However, insufficient knowledge of phage biology, low quality
control of phage preparations and lack of solid scientific evidence of therapeutic successes led
to phage failure over the newly discovered antibiotics till the second half of the twentieth
century.
The alarming emergence of antibiotic resistant bacteria is considered the greatest threat to
human health of the new millennium by both the Infectious Diseases Society of America (IDSA)
and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in addition
to many other health-caring organizations worldwide (El-Tahawy, 2004; Rice, 2009). With this
new reality, scientific community and business players have revived their interest in phages as
an alternative therapy. The ability of phages to kill antibiotic-resistant bacteria allied with their
ubiquitous nature, high specificity (minimal disruption of normal flora), prevalence in human
gastrointestinal tract, self-replication ability at the infection site, and low inherent toxicity qualifies
them probably as the most “safe” and “green” technology available for clinical application. Several
studies are currently providing convincing evidence regarding the safety and efficiency of phage
therapy in animals and humans (Sulakvelidze et al., 2001; Sillankorva et al., 2012), with recent
appearances of new phage companies and commercial phage-based products (Thiel, 2004; Housby
and Mann, 2009).
This opinion article reports on a number of bacterial pathogens for which virulent
phages can still be isolated but till now have been neglected due to various reasons listed
below.
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Finding the Next Phage—the Road Ahead
for Phage Therapy
With the renewed excitement and the successive regulatory
affairs opening for phage application, the possibility to use
phage products designed “a la carte” to treat therapeutically
every bacterial infections seems endless (Brüssow and Hendrix,
2002; Rohwer, 2003; Pirnay et al., 2010). In recent years, FDA
has approved phage preparations to be used as food additives
(e.g., Listex, EcoShield) (FDA, 2006). Also, the World Medical
Association in its Declaration of Helsinki provides a way for
phage therapy, as a representative of non-conventional type
of medicine, to be used complying the ethical principles for
medical research involving human subjects (World Medical
and Association, 1964/2013). European regulatory authorities
nowadays consider phages as biological agents which accordingly
require European trials to follow the current biological medicinal
product guidelines, while trials in the USA need to be complied
with the guidelines of the division of vaccines and related
product applications. However to date, no phage therapy-specific
guidelines have been published by any of these authorized
agencies.
From a therapeutic perspective, strictly lytic phages are
required to lyse pathogenic bacteria and persist by releasing
virion progeny that can migrate to other sites in the body. The
currently revived attention toward phage therapy is mostly due to
the worldwide emergence of antibiotic-resistant bacterial species,
known before as either opportunistic or rare pathogens. A
good example for this phenomenon is Acinetobacter baumannii:
known as a low-grade pathogen in the 70 s (Joly-Guillou, 2005)
and currently listed as one of the six top-priority microorganisms
by IDSA (Boucher et al., 2009). However, despite the growing
therapeutic appreciation of phages, there are still many human
bacterial pathogens, according to the approved list of biological
agents (Health Safety and Executive, 2013), for which lytic
phages have not yet been found, including representatives of
important biosafety level 3 bacteria, such as Rickettsia, Ehrlichia,
and Coxiella. Although these bacteria are not an eminent
public health hazard, low infectious doses of them can cause
severe to fatal diseases (ehrlichiosis, epidemic typhus, and Rocky
Mountain spotted fever and Q fever). Within the same safety
category, severalMycobacteria species, likeM. africanum, andM.
leprae, the latter etiological agent of Hansen’s disease (leprosy),
have not yet been targeted by phage therapy either. Depending
on the type, nature and source of infection, we envisage several
novel phage applications.
Wound and Skin Infections
Wounds and burns cause breaches in the natural protective
skin barrier, making it susceptible to infection. Several skin
conditions are caused byM. marinum,M. szulgai, or Treponema
pertenue. In case of chronic wounds, Actinomycetes and
Actinomadura are responsible for a subcutaneous subacute-
to-chronic actinomycosis and mycetoma, respectively. Topical
solutions, such as ointments, creams or lotions containing lytic
phages could be incorporated in cosmetic and pharmaceutical
industry products to treat these conditions. For purulent
chronic wounds, phages can be applied in the course of
wound irrigation, either by injection into/around the wound,
by soaked bandages, or by impregnation into biodegradable
polymer wound dressings with a time-release manner. The
major challenge in treating skin infections caused by intracellular
bacteria including Mycobacterium spp. is to develop appropriate
strategies for delivery of bacteriophages into mammalian cells
(Chacko et al., 2012). Nonetheless several intracellular pathogens
have a temporary extracellular living form where they can be
more easily tackled by phages; this is the case of M. ulcerans,
against which phage therapy has been proven efficient (Trigo
et al., 2013).
Respiratory, Gastrointestinal, and Urogenital
Tract Infections
The bacterial colonization of mucous membranes provides a
potential starting point for more severe and sometimes life-
threatening infections. Phages specific for Klebsiella pneumonia,
A. baumannii, Pseudomonas aeruginosa, and Staphylococcus
aureus have been extensively studied. However, there are
other pathogens involved in severe respiratory infections
still uncovered by phage therapy: Haemophilus influenzae
(bronchitis), Corynebacterium diphtheria (diphteria), and
Porphyromonas spp. are responsible for upper respiratory tract
infections; Helicobacter pylori,M. simiae, or Nocardia spp. infect
the lower respiratory tract as well as Fluoribacter bozemanae,
Mycoplasma pneumoniae, or Ureaplasma urealyticum presenting
etiological agents of pneumonia. In this type of infections,
effective phage administration can be done via the respiratory
route by aerosol inhalation. No lytic phages are available
to fight enteric infections caused by Salmonella arizonae,
Porphyromonas spp., Providencia alcalifaciens, Hafnia alvei,
or Serpulina spp. Gastrointestinal phage treatment offers
advantages over antibiotics by the reduced disruption of the
gut flora. However, phages are sensitive to the low pH of the
gastrointestinal tract, therefore should be encapsulated when
delivered orally, as already tested in vivo studies in feedlot cattle
with Escherichia coli O157:H7 phages (Callaway et al., 2008).
Concerning urogenital tract infections, there are no known lytic
phages for Legionella pneumophila and Proteus penneri or P.
rettgeri and Citrobacter koseri species responsible for nosocomial
urinary tract infections. Treating urogenital infections with
phages can be similar to conventional methods involving
antibiotic applications (e.g., intramuscular/subcutaneous
injections or irrigation of bladder). In this context, the use of
indwelling hydrogel-coated catheters combined with phages
may be a very attractive approach for managing these particular
bacterial infections in hospitals. As far as bacterial vaginosis
is concerned, Gardnerella vaginalis lytic phages could be an
interesting therapeutic option when impregnated into tampons
or personal hygiene products. Additionally, phage therapy
can potentially target bacteria causing sexually transmitted
infections, such as chancroid (Haemophilus ducreyi), chlamydia
(Chlamydia trachomatis), gonorrhea (Neisseria gonorrhoeae),
syphilis (Treponema pallidum), and granuloma inguinale
(Klebsiella granulomatis).
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Bacteremia and Septicemia
The presence of viable bacteria in the human circulating blood,
known as bacteremia, can result in systemic infections. Common
localized infections, like pneumonia, urinary tract or bladder and
skin infections may become systemic too. Relevant pathogens
causing systemic infections are for example: Francisella
spp. (tularemia), Leptospira interrogans (leptospirosis),
Brucella canis (brucellosis), Ehrlichia sennetsu (monocytic
ehrlichiosis), Rickettsia spp. (e.g., typhus, rickettsialpox, Rocky
Mountain spotted fever), Treponema spp. (syphilis and yaws),
Peptostreptococcus anaerobius (endocarditis) or Clostridium
tetani and botulinum (tetanus and botulism). Intravenous and
parenteral delivery of phages are considered the most routinely-
employed methods of administration, supplying sufficient
numbers of phages to eliminate bacteria from the bloodstream.
Transdermal delivery also offers a potential means of overcoming
many problems associated with systemic phage administration.
(UN)Expected Challenges
One can anticipate several challenging factors of therapeutic and
biotechnology development of phages, as depicted in Figure 1.
Intrinsic-driven factors are not discussed here but refer to
phage profile (e.g., virulent or temperate nature, specificity,
burst size), stability (e.g., pH, temperature), concentration (ideal
multiplicity of infection is phage dependent), environmental
factors and its inherent ability to induce bacterial resistance.
These limitations have been extensively discussed elsewhere
(Loc-Carrillo and Abedon, 2011). External factors can be
considered more problematic as they are difficult to anticipate
and resolve, such as: (i) Phage isolation, difficulties can be
expected in the isolation of some of the phages, already
a demanding task that can become even more challenging
for phages targeting fastidious hosts as their availability and
likelihood of being found in the environment are relatively
low; (ii) Phage toxicity, although considered inherently non-
toxic, due to its nucleic acid and protein nature, phages
are produced in the presence of bacterial hosts, therefore
a careful design of the downstream processes is required
to avoid the presence of any bacterial toxins in the phage
product (Merabishvili et al., 2009). The factor of releasing
endotoxins after bursting bacterial cells inside the human
body may limit phage treatment of Gram-negative systemic
infections too, however the same challenges exist for some
antibiotics and more detailed studies will be needed for each
specific phage and bacterial host; (iii) Phage neutralization,
some studies have shown that phages are removed by the
reticuloendothelial system and inactivated by the development
of neutralizing antibodies like most pharmaceuticals that interact
with the body’s immune system (Westwater et al., 2003; Lusiak-
Szelachowska et al., 2014). Although the risks are minimal
because of low speed of these processes and non-dependence
of successful outcome on anti-phage activity of human immune
system (Lusiak-Szelachowska et al., 2014), the delivery of less-
immunogenic phages either with proper nanocarriers (e.g.,
liposomes) or by engineering them to have non-immunogenic
and biocompatible peptides on their surface (e.g., polyethylene
glycol molecules) are considered; (iv) Phage access to host; the
choice of the delivery system plays a key role in the success
of phage therapy. Recent advances in phage therapy show that
targeted delivery has been more successful for localized infection
treatment, while for systemic infections the parenteral route is
recommended (Ryan et al., 2011). Treatment of intracellular
bacterial infections remains the main challenge for medical
FIGURE 1 | Schematic representation of factors that limit phage therapy.
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care. As mentioned above, obligatory or facultative intracellular
bacterial pathogens either reproducing themselves and thriving
in cells, such as M. leprae, Chlamydia, Ehrlichia, and Rickettsia
or taking transient refuge therein are shielded from many
antimicrobials, hence phage therapy may fail too. Finally, and
probably the most important barriers in phage therapy are still
(iv) Regulatory acceptance and (v) Lack of public awareness. It
is not clear yet, which is the best regulatory framework for phase
therapy: can phages be considered medicinal products, biological
medicinal products or advanced medicinal products, according
to Directive 2001/83/EC. Several arguments recently debated
by experts representing different stakeholder groups, fit phage
therapy partially (but not totally) in every possible definition.
This turns regulation of phage products currently difficult to
achieve, unless a dedicated European legal framework is created
(Verbeken et al., 2014). This “marketing” authorization should
also contemplate legislation either for a standard phage-based
product or for more specific, tailor-made phage preparations.
Overall, the uncertainty of phage-specific regulatory guidelines
along with the patentability difficulties, hurdles the potential of
pharmaceutical investments. This is practically critical in the
Western world, where there is also a low awareness of the
potential of phage therapy by large part of medical society.
Besides exploiting various therapeutic applications, a tremendous
effort is still needed in phage therapy research and on the
regulatory side, to bring phages from the bench to the patient’s
bedside.
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